Breast Cancer Archives | VJOncology

The Breast Cancer Channel on VJOncology is supported by Gilead. These supporters have no influence over the production of the content.

View overview page

I-SPY2.2: emerging biomarkers in breast cancer

Denise Wolf • 4 Jun 2023

Emerging toxicities associated with ADCs

Sung-Bae Kim • 11 May 2023

ADCs: is chemotherapy dead?

Eva Ciruelos • 16 Mar 2023

Optimizing treatment in patients with early-stage HER2-positive breast cancer

Hope S. Rugo • 17 Mar 2023

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

Ian Krop • 7 Dec 2022

N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer

Saranya Chumsri • 8 Dec 2022

neoHIP: neoadjuvant HER2-targeted therapy +/- IO with pembrolizumab

Heather McArthur • 7 Dec 2022

DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer

Ian Krop • 8 Dec 2022

HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC

Erika Hamilton • 15 Dec 2022

Remaining questions surrounding HER2-low breast cancer – how low can you go?

Paolo Tarantino • 8 Dec 2022

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Erika Hamilton • 15 Dec 2022

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Erika Hamilton • 15 Dec 2022

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

Erika Hamilton • 15 Dec 2022

Anti-HER2 CAR macrophages for solid tumors

Yara Abdou • 13 Dec 2022

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

Paolo Tarantino • 8 Dec 2022

Immunotherapy in breast cancer

Jon Amund Kyte • 8 Dec 2022

1
2
3
4
5
…
8
Next